|
摘要：
|
|
摘要：目的 探讨利拉鲁肽对2型糖尿病合并非酒精性脂肪性肝病（non-alcoholic fatty
liver disease，NAFLD）患者糖脂代谢及胰岛素抵抗的影响。方法 回顾性分析2018年
1月至2020年1月于新疆医科大学第七附属医院就诊的84例2型糖尿病合并NAFLD患者的
临床资料，根据用药不同分为观察组（43例）和对照组（41例），对照组患者采用二
甲双胍治疗，观察组患者采用二甲双胍联合利拉鲁肽治疗，疗程3个月。检测两组患者
治疗前后血糖（空腹血糖、餐后2 h血糖、糖化血红蛋白）、血脂（甘油三酯、总胆固
醇、低密度脂蛋白、高密度脂蛋白）、胰岛素抵抗指数、胰岛β-细胞功能指数、脂肪
肝严重程度、体重指数（body mass index，BMI）、肝功能 [丙氨酸氨基转移酶（alanine
aminotransferase，ALT）、天门冬氨酸氨基转移酶（aspartate aminotransferase，
AST）]，记录患者不良反应。结果 ①治疗后，两组患者空腹血糖 [观察组：（5.42 ±
0.63）mmol/L vs（8.87 ± 0.65）mmol/L；对照组：（6.49 ± 0.55）mmol/L vs（8.92 ±
0.71）mmol/L]、餐后2 h血糖 [观察组：（8.27 ± 0.95）mmol/L vs（13.84 ± 1.25）mmol/L；
对照组：（11.19 ± 1.04）mmol/L vs（13.69 ± 1.18）mmol/L] 和糖化血红蛋白 [观
察组：（5.62 ± 0.64）% vs（7.37 ± 0.87）%；对照组：（6.34 ± 0.71）% vs（7.44 ±
0.75）%] 水平均较治疗前显著降低，且观察组显著低于对照组（P均＜ 0.05）。②治
疗后，两组患者甘油三酯 [观察组：（1.80 ± 0.27）mmol/L vs（3.12 ± 0.37）mmol/L；对
照组：（2.51 ± 0.32）mmol/L vs（3.05 ± 0.41）mmol/L]、总胆固醇 [观察组：（5.31 ±
0.59）mmol/L vs（6.70 ± 0.67）mmol/L；对照组：（5.94 ± 0.65）mmol/L vs（6.64 ±
0.73）mmol/L] 和低密度脂蛋白 [观察组：（2.42 ± 0.27）mmol/L vs（3.59 ± 0.39）mmol/L；
对照组：（2.93 ± 0.31）mmol/L vs（3.65 ± 0.34）mmol/L] 水平均显著低于治疗前，高
密度脂蛋白水平显著高于治疗前 [观察组：（1.63 ± 0.53）mmol/L vs（1.21 ± 0.40）mmol/L；
对照组：（1.33 ± 0.41）mmol/L vs（1.16 ± 0.37）mmol/L]，差异有统计学意义（P
均＜ 0.05）。治疗后，观察组甘油三酯、总胆固醇和低密度脂蛋白水平均显著低于对
照组，高密度脂蛋白水平高于对照组，差异有统计学意义（P均＜ 0.05）。③治疗后，
两组患者胰岛素抵抗指数（观察组：2.59 ± 0.43 vs 5.71 ± 0.59；对照组：3.46 ± 0.51 vs
5.58 ± 0.67）和胰岛β-细胞功能指数（152.71 ± 8.84 vs 105.42 ± 8.34；对照组：126.45 ±
9.35 vs 105.05 ± 8.02）均较治疗前显著改善，与对照组相比，观察组治疗后胰岛素抵
抗指数显著降低，胰岛β-细胞功能指数显著升高（P均＜ 0.05）。④治疗后，观察组
（正常/轻度/中度/重度：12例/19例/9例/1例 vs 0例/16例/17例/8例）和对照组（正常/轻
度/中度/重度：8例/15例/17例/3例 vs 0例/14例/18例/11例）患者脂肪肝严重程度均较治
疗前显著改善，且观察组脂肪肝严重程度较对照组轻（z = 2.029，P = 0.042）。⑤治疗
后，两组患者BMI [观察组：（19.97 ± 2.66）kg/m2 vs（24.88 ± 3.28）kg/m2
；对照组：
（22.11 ± 3.08）kg/m2 vs（24.94 ± 3.30）kg/m2
]、ALT [观察组：（21.27 ± 5.26）U/L
vs（41.02 ± 9.83）U/L；对照组：（33.41 ± 5.02）U/L vs（40.94 ± 9.80）U/L] 及AST [观察
组：（24.23 ± 3.69）U/L vs（36.33 ± 6.70）U/L；对照组：（30.50 ± 5.04）U/L vs（36.18 ±
6.63）U/L] 均显著低于治疗前，且观察组显著低于对照组（P均＜ 0.05）。⑥观察组
和对照组不良反应发生率分别为14.63%（6/41）、9.30%（4/43），差异无统计学意义
（χ2 = 0.174，P = 0.676）。结论 利拉鲁肽可改善2型糖尿病合并NAFLD患者的糖脂代
谢和胰岛素抵抗，减轻脂肪肝严重程度，且安全性较好。
|
|
Abstract: Objective To investigate the effects of liraglutide on glucose and lipid metabolism
and insulin resistance in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease
(NAFLD). Methods The clinical data of 84 patients with type 2 diabetes mellitus complicated
with NAFLD in the Seventh Affiliated Hospital of Xinjiang Medical University from
January 2018 to January 2020 were retrospectively analyzed. The patients were divided into
observation group (43 cases) and control group (41 cases) according to the different treatment.
Patients in control group were treated with metformin and patients in observation group were
treated with metformin combined with liraglutide for 3 months. Glucose indexes (fasting
plasma glucose, 2 h postprandial blood glucose, glycosylated hemoglobin), lipid metabolism
indexes (triglyceride, total cholesterol, low density lipoprotein, high density lipoprotein),
insulin resistance index, islet β cell function index, severity of fatty liver, body mass index
(BMI), liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST)] and
adverse reactions were observed before and after treatment. Results ①After treatment, the
fasting blood glucose [observation group: (5.42 ± 0.63) mmol/L vs (8.87 ± 0.65) mmol/L;
control group: (6.49 ± 0.55) mmol/L vs (8.92 ± 0.71) mmol/L], 2 h postprandial blood glucose
[observation group: (8.27 ± 0.95) mmol/L vs (13.84 ± 1.25) mmol/L; control group: (11.19 ±
1.04) mmol/L vs (13.69 ± 1.18) mmol/L] and glycosylated hemoglobin [observation group:
(5.62 ± 0.64)% vs (7.37 ± 0.87)%; control group: (6.34 ± 0.71)% vs (7.44 ± 0.75)%] levels
of patients in two groups were significantly lower than those before treatment, and the above
indexes of patients in observation group were significantly lower than those of control group
(all P ＜ 0.05). ②After treatment, the triglyceride [observation group: (1.80 ± 0.27) mmol/L vs
(3.12 ± 0.37) mmol/L; control group: (2.51 ± 0.32) mmol/L vs (3.05 ± 0.41) mmol/L], total
cholesterol [observation group: (5.31 ± 0.59) mmol/L vs (6.70 ± 0.67) mmol/L; control group:
(5.94 ± 0.65) mmol/L vs (6.64 ± 0.73) mmol/L] and low density lipoprotein [observation group:
(2.42 ± 0.27) mmol/L vs (3.59 ± 0.39) mmol/L; control group: (2.93 ± 0.31) mmol/L vs (3.65 ±
0.34) mmol/L] levels of patients in two groups were significantly lower than those before
treatment, the high density lipoprotein level was significantly higher than that before treatment
[observation group: (1.63 ± 0.53) mmol/L vs (1.21 ± 0.40) mmol/L; control group: (1.33 ±
0.41) mmol/L vs (1.16 ± 0.37) mmol/L], the differences were statistically significant (all P ＜
0.05). After treatment, the levels of triglyceride, total cholesterol and low-density lipoprotein
of patients in observation group were significantly lower than those of control group, and
the level of high-density lipoprotein was higher than that of control group, the differences
were statistically significant (all P ＜ 0.05). ③Compared with those before treatment, insulin
resistance index (observation group: 2.59 ± 0.43 vs 5.71 ± 0.59; control group: 3.46 ± 0.51
vs 5.58 ± 0.67) and islet β cell function index (observation group: 152.71 ± 8.84 vs 105.42 ±
8.34; control group: 126.45 ± 9.35 vs 105.05 ± 8.02) of patients in two groups improved
significantly after treatment (all P ＜ 0.05). Compared with those in control group, the
insulin resistance index of patients in observation group decreased significantly and islet β
cell function index increased significantly after treatment (all P ＜ 0.05). ④After treatment,
the fatty liver severity of patients in observation group (normal/mild/moderate/severe: 12 cases/
19 cases/9 cases/1 case vs 0 case/16 cases/17 cases/8 cases) and control group (normal/mild/
moderate/severe: 8 cases/15 cases/17 cases/3 cases vs 0 case/14 cases/18 cases/11 cases) improved
significantly, which was lighter in observation group than that in control group (z = 2.029, P = 0.042).
⑤After treatment, BMI [observation group: (19.97 ± 2.66) kg/m2 vs (24.88 ± 3.28) kg/m2
; control
group: (22.11 ± 3.08) kg/m2 vs (24.94 ± 3.30) kg/m2
], ALT [observation group: (21.27 ± 5.26) U/L
vs (41.02 ± 9.83) U/L; control group: (33.41 ± 5.02) U/L vs (40.94 ± 9.80) U/L] and AST
[observation group: (24.23 ± 3.69) U/L vs (36.33 ± 6.70) U/L; control group: (30.50 ± 5.04) U/L
vs (36.18 ± 6.63) U/L] levels of patients in two groups were significantly lower than those before
treatment, and the above indexes of patients in observation group were significantly lower than those
of control group (all P ＜ 0.05). ⑥The incidence of adverse reactions of patients in observation
group and control group were 14.63% (6/41) and 9.30% (4/43), respectively, the difference was not
statistically significant (χ2 = 0.174, P = 0.676). Conclusions Liraglutide can improve glucose and
lipid metabolism, insulin resistance and the severity of fatty liver disease of type 2 diabetes mellitus
patients with NAFLD, with good safety.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|